Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Aspergillosis

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 56 12 74 52 58 54 42 3 43 15 17 71 32
Aspergillosis, Susceptibility to 56 29 13 6 39
Infection Due to Aspergillus 12


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:13564
OMIM 56 614079
ICD9CM 34 117.3
MeSH 43 D001228
NCIt 49 C2886
SNOMED-CT 67 65553006
ICD10 32 B44 B44.9
MESH via Orphanet 44 D001228
ICD10 via Orphanet 33 B44.0 B44.1 B44.2 more
UMLS via Orphanet 72 C0004030
Orphanet 58 ORPHA1163
UMLS 71 C0004030

Summaries for Aspergillosis

NIH Rare Diseases : 52 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue . Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer , AIDS, leukemia, organ transplantation, chemotherapy , or other conditions or events that reduce the number of normal white blood cells . In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma , a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess , is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells . The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to allergic bronchopulmonary aspergillosis and invasive aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC1A (C-Type Lectin Domain Family 1 Member A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Guaifenesin and Benralizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM : 56 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079)

MedlinePlus : 42 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 74 Aspergillosis is the name given to a wide variety of diseases caused by fungal infections from species... more...

Related Diseases for Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 allergic bronchopulmonary aspergillosis 34.8 SFTPD MBL2 IL5 IL4 IL10 IFNG
2 invasive aspergillosis 33.8 TLR9 TLR6 TLR4 TLR2 SFTPD PTX3
3 neuroaspergillosis 33.0 TLR2 CLEC7A
4 neutropenia 32.1 MBL2 ELANE CSF3 CSF1
5 bronchiectasis 31.9 TLR2 MBL2 ELANE CFTR
6 hypereosinophilic syndrome 31.8 IL5 IL4 IL10 IFNG
7 mucormycosis 31.8 IFNG CSF3 CLEC7A CCR6
8 cystic fibrosis 31.7 TLR4 SFTPD MBL2 IL10 ELANE CFTR
9 chronic granulomatous disease 31.5 TLR9 IFNG ELANE CSF3
10 respiratory failure 31.4 SFTPD PTX3 IL5 IL10 ELANE CFTR
11 rhinitis 31.4 IL5 IL4 IL10 IFNG
12 pulmonary tuberculosis 31.3 TLR4 TLR2 MBL2 IL4 IL10 IFNG
13 candidiasis 31.3 TLR4 TLR3 TLR2 MBL2 IL4 IL10
14 bronchopneumonia 31.3 TLR4 IL10 ELANE
15 eosinophilic pneumonia 31.3 SFTPD IL5 IL4
16 acute graft versus host disease 31.2 IL4 IL10 IFNG CSF3
17 toxic shock syndrome 31.2 TLR4 TLR2 IL4 IL10 IFNG
18 acquired immunodeficiency syndrome 31.2 IL10 IFNG CCR6 CCL3
19 ige responsiveness, atopic 31.2 IL5 IL4 IL10 IFNG
20 cryptococcosis 31.2 MBL2 IL4 IL10 IFNG CLEC7A CCR6
21 osteomyelitis 31.2 TLR4 TLR2 IL4 IL10 IFNG CSF3
22 endocarditis 31.2 TLR6 TLR2 IL10 IFNG
23 sarcoidosis 1 31.1 SFTPD IFNG CCR6 CCL3
24 idiopathic interstitial pneumonia 31.1 TLR9 SFTPD IL4 IFNG ELANE CCR6
25 bronchitis 31.0 TLR4 TLR2 IL5 IL4 IL10 ELANE
26 pneumocystosis 31.0 SFTPD CSF3 CLEC7A CCR6
27 histoplasmosis 31.0 IFNG CLEC7A CCR6
28 immune deficiency disease 31.0 MBL2 IL4 IL10 IFNG CCR6 CCL3
29 spondylitis 31.0 IL10 IFNG CCR6
30 lymphopenia 31.0 IL4 IL10 IFNG CCR6
31 bronchiolitis obliterans 30.9 TLR4 SFTPD IL10 IFNG
32 chronic graft versus host disease 30.9 IL10 IFNG
33 aplastic anemia 30.9 TLR9 IL4 IL10 IFNG CSF3 CSF1
34 allergic rhinitis 30.9 IL5 IL4 IL10 IFNG
35 pulmonary eosinophilia 30.9 SFTPD IL5 IL4 CCL3
36 chronic eosinophilic pneumonia 30.8 IL5 CSF3 CCL3
37 interstitial lung disease 30.8 SFTPD IL5 IL4 IL10 IFNG
38 coccidioidomycosis 30.8 TLR4 MBL2 CLEC7A CCR6
39 pyelonephritis 30.8 TLR4 MBL2 IL10 IFNG CSF3
40 echinococcosis 30.8 TLR4 TLR2 IL5 IL10 IFNG
41 diarrhea 30.8 TLR4 IL5 IL10 IFNG CSF3 CFTR
42 fungal keratitis 30.8 TLR4 TLR2 CLEC7A
43 myocarditis 30.8 TLR4 TLR3 IL4 IL10 IFNG
44 neuritis 30.7 IL4 IL10 IFNG CCL3
45 exanthem 30.7 IL10 CSF3 CCR6
46 silicosis 30.7 TLR4 SFTPD IL4 IL10
47 extrinsic allergic alveolitis 30.7 SFTPD IL10 ELANE CCR6 CCL3
48 cellulitis 30.7 IL5 IL10 CCR6
49 allergic asthma 30.7 TLR4 TLR2 IL5 IL4 IL10 IFNG
50 pulmonary disease, chronic obstructive 30.7 TLR4 TLR2 SFTPD IL5 IL4 IL10

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):

Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:

Diseases related to Aspergillosis

Symptoms & Phenotypes for Aspergillosis

Clinical features from OMIM:


UMLS symptoms related to Aspergillosis:

fever, pruritus

GenomeRNAi Phenotypes related to Aspergillosis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCL3 CCR6 CLEC7A CSF1 CSF3 IL5

MGI Mouse Phenotypes related to Aspergillosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
2 immune system MP:0005387 10.28 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
3 homeostasis/metabolism MP:0005376 10.24 CCR6 CFTR CLEC7A CSF1 ELANE IFNG
4 digestive/alimentary MP:0005381 10.09 CFTR CLEC7A IFNG IL10 IL4 IL5
5 liver/biliary system MP:0005370 9.86 CFTR CSF1 IFNG IL10 IL4 IL5
6 neoplasm MP:0002006 9.7 ELANE IFNG IL10 IL5 TLR2 TLR3
7 reproductive system MP:0005389 9.65 CFTR CSF1 IFNG IL10 IL4 IL5
8 respiratory system MP:0005388 9.4 CFTR CLEC7A CSF1 IFNG IL10 IL4

Drugs & Therapeutics for Aspergillosis

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2 Benralizumab Approved, Investigational Phase 4 1044511-01-4
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Omalizumab Approved, Investigational Phase 4 242138-07-4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
13 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
14 Antitussive Agents Phase 4
15 Trace Elements Phase 4
16 Vitamins Phase 4
17 Micronutrients Phase 4
18 Ergocalciferols Phase 4
19 Nutrients Phase 4
20 Calcium, Dietary Phase 4
21 Calciferol Phase 4
22 Vitamin D2 Phase 4
23 Antibodies, Monoclonal Phase 4
24 Immunoglobulin G Phase 4
25 Immunologic Factors Phase 4
26 Anti-Bacterial Agents Phase 4
27 Liposomal amphotericin B Phase 4
Hydroxyitraconazole Phase 4
29 Anti-Asthmatic Agents Phase 4
30 Immunoglobulin E Phase 4
31 Respiratory System Agents Phase 4
32 Antibodies Phase 4
33 Immunoglobulins Phase 4
34 Anti-Allergic Agents Phase 4
35 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
36 glucocorticoids Phase 4
37 Pharmaceutical Solutions Phase 4
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
deoxycholic acid Approved Phase 3 83-44-3 222528
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
Natamycin Approved Phase 3 7681-93-8 5281099
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
45 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 62924
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Pirfenidone Approved, Investigational Phase 2, Phase 3 53179-13-8 40632
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 217)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
6 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
7 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
8 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
9 Pharmacokinetics of Voriconazole in Obese Subjects Completed NCT01030653 Phase 4 Voriconazole low dose;Voriconazole high dose
10 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
11 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
12 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
13 A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
14 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
15 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
16 Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis Not yet recruiting NCT04108962 Phase 4 Fasenra, 30 Mg/mL Subcutaneous Solution
17 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Not yet recruiting NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
18 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
19 An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
20 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
21 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
22 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
23 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
24 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
25 Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment Withdrawn NCT02020213 Phase 4 Posaconazole
26 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
27 Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial Unknown status NCT03230058 Phase 2, Phase 3 Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
28 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
29 Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts Completed NCT00159822 Phase 2, Phase 3 Voriconazole
30 Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
31 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole
32 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
33 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
34 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
35 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
36 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
37 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
38 A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
39 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
40 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
41 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
42 A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
43 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
44 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
45 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
46 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
47 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
48 A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant Completed NCT00001937 Phase 3 FK463;Fluconazole
49 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
50 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001757 Phase 3 Voriconazole

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Caspofungin acetate
Miconazole Nitrate

Cochrane evidence based reviews: aspergillosis

Genetic Tests for Aspergillosis

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 29 CLEC1A CLEC7A

Anatomical Context for Aspergillosis

MalaCards organs/tissues related to Aspergillosis:

Lung, Testes, Liver, Bone, Myeloid, Bone Marrow, Brain

Publications for Aspergillosis

Articles related to Aspergillosis:

(show top 50) (show all 12663)
# Title Authors PMID Year
Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. 6 61 56
20807886 2010
Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. 56 6
29489751 2018
Toll-like receptor 4 polymorphisms and aspergillosis. 56 61 54
19202579 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 54 56 61
19202580 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 61 56 54
19196681 2009
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 54 61 56
18946062 2008
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. 56 61 54
18275280 2008
Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. 56 61
16247433 2005
Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. 42 61
31478559 2019
Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis. 42 61
31387539 2019
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data. 42 61
31138134 2019
Human dectin-1 deficiency and mucocutaneous fungal infections. 6
19864674 2009
TLR polymorphisms and the risk of invasive fungal infections. 56
18946070 2008
Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. 56
11470510 2001
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. 61 54
20413160 2010
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. 54 61
19827955 2009
Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. 54 61
18718399 2008
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. 54 61
17335555 2007
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. 61 54
17311505 2007
Chemokines in allergic aspergillosis--from animal models to human lung diseases. 61 54
17168792 2006
[Clinical analysis of chronic pulmonary aspergillosis and discovery of an elastase inhibitor]. 54 61
16940951 2006
[A case of idiopathic pulmonary upper lobe fibrosis complicated by invasive pulmonary aspergillosis]. 61 54
12772600 2003
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]. 61 54
11979751 2002
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. 54 61
11474427 2001
Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. 54 61
11500084 2001
A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. 54 61
11499676 2001
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. 61 54
11254642 2001
Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. 54 61
10878372 2000
[Aspergillosis: Mechanisms of pathogenicity implicated and approach to laboratory diagnosis.]. 54 61
17655396 1998
Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. 61 54
9367408 1997
Polymerase chain reaction amplification of Asp f I and alkaline protease genes from fungus balls: clinical application in pulmonary aspergillosis. 61 54
9058095 1997
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation]. 61 54
8691669 1996
[Protective effect of human macrophage colony-stimulating factor on fungal infection (2). In vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage]. 61 54
7602192 1995
Western blot detection of IgG anti-Aspergillus fumigatus elastase in sera of patients with aspergillosis. 54 61
7965494 1994
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. 54 61
1452348 1992
Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease. 54 61
1655460 1991
[Aspergillus mastoiditis in infected granulomatosis--a case report]. 54 61
2165779 1990
Molecular Mechanisms of Conidial Germination in Aspergillus spp. 61
31801804 2020
Alfa-1-antitrypsin deficiency: a predisposing factor leading to invasive infections? 61
31749396 2020
Oral administration of voriconazole with surgical fungal plaque debridement for the treatment of sinonasal aspergillosis with cribriform plate lysis in three dogs. 61
31841098 2020
Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level. 61
31350185 2020
The impact of comorbidities on severe asthma. 61
31644439 2020
Mutation in cyp51A and high expression of efflux pump gene of Aspergillus fumigatus induced by propiconazole in liquid medium and soil. 61
31662261 2020
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. 61
31520441 2019
Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies. 61
31599334 2019
Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study. 61
31598932 2019
Twice-Weekly Tacrolimus Can Overcome Pharmacologic Interaction and Help in the Successful Treatment of Pulmonary Aspergillosis in a Liver Transplant Recipient. 61
30373507 2019
Clinical application of Aspergillus lateral flow device in bronchoalveolar lavage fluid of patients with classic risk factors for invasive pulmonary aspergillosis. 61
31581342 2019
Aspergillus felis in Patient with Chronic Granulomatous Disease. 61
31742513 2019
Host defense mechanisms against Aspergillus fumigatus lung colonization and invasion. 61
31103956 2019

Variations for Aspergillosis

ClinVar genetic disease variations for Aspergillosis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CLEC1A NM_016511.4(CLEC1A):c.77G>C (p.Gly26Ala)SNV risk factor 590287 12:10251445-10251445 12:10098846-10098846
2 CLEC7A NM_197948.3(CLEC7A):c.*25T>GSNV Benign 4466 rs16910526 12:10271087-10271087 12:10118488-10118488

Expression for Aspergillosis

Search GEO for disease gene expression data for Aspergillosis.

Pathways for Aspergillosis

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.69 TLR4 IL5 IL4 IL10 IFNG CSF3
Show member pathways
13.36 IL5 IL4 IL10 IFNG CSF3 CSF1
Show member pathways
13.36 TLR9 TLR6 TLR4 TLR3 TLR2 IL5
Show member pathways
13.31 IL5 IL4 IL10 CSF3 CSF1 CCR6
Show member pathways
13.22 TLR9 TLR6 TLR4 TLR3 TLR2 IL4
Show member pathways
Show member pathways
12.99 TLR4 TLR3 TLR2 IL4 CSF3 CSF1
Show member pathways
Show member pathways
12.71 TLR9 TLR6 TLR4 TLR3 TLR2
Show member pathways
12.67 TLR9 TLR4 TLR2 IL5 IL4 IL10
Show member pathways
12.64 TLR4 TLR2 IL5 IL4 IL10 IFNG
13 12.63 TLR9 TLR6 TLR3 TLR2 IL4 IL10
Show member pathways
12.61 TLR9 TLR6 TLR4 TLR3 TLR2
Show member pathways
12.44 TLR9 TLR6 TLR4 TLR3 TLR2
Show member pathways
Show member pathways
12.39 IL5 IL4 IL10 IFNG CSF3
Show member pathways
12.33 IL10 CSF1 CCR6 CCL3
Show member pathways
12.32 TLR9 TLR6 TLR4 TLR3 TLR2
Show member pathways
12.31 TLR4 TLR2 IL4 IL10 IFNG
21 12.26 TLR9 TLR6 TLR4 TLR2 IL10 IFNG
22 12.25 TLR9 TLR6 TLR4 TLR3 TLR2 IFNG
Show member pathways
Show member pathways
12.09 TLR9 TLR6 TLR4 TLR3 TLR2 IL5
26 12.04 IL5 IL4 IL10 IFNG CSF3 CSF1
27 11.96 TLR4 TLR2 IL10 IFNG
28 11.96 TLR4 TLR2 IFNG CSF1 CCL3
29 11.95 IL5 IL4 CSF3 CSF1
Show member pathways
11.91 TLR9 TLR6 TLR4 TLR3 TLR2 IL10
31 11.82 TLR9 IL10 IFNG CSF1
32 11.81 TLR9 TLR6 TLR4 TLR3 TLR2 CLEC7A
33 11.8 IL5 IL4 IFNG
34 11.79 IL4 IL10 IFNG CCL3
35 11.78 TLR4 IFNG CCL3
Show member pathways
Show member pathways
11.76 IL5 IL4 IFNG
38 11.75 IL5 IL4 IL10 IFNG CCR6 CCL3
39 11.73 PTX3 IL5 IL4 CSF3 CCL3
40 11.67 IL5 IL4 IL10
41 11.6 TLR4 TLR2 IFNG CSF1
42 11.6 IL4 IL10 CSF3 CSF1 CCL3
43 11.57 IL5 IL4 IL10 IFNG
44 11.54 IL5 CSF3 CSF1
45 11.42 TLR9 IL10 IFNG
46 11.36 IL5 IL4 IFNG
47 11.34 IL5 IL4 IFNG
48 11.33 TLR9 TLR4 TLR2 IL10 IFNG CSF3
49 11.29 IL5 IL4 IL10 IFNG
50 11.05 IL5 IL4 IL10 CSF3 CSF1 CCL3

GO Terms for Aspergillosis

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TLR9 SFTPD PTX3 MBL2 IL5 IL4
2 endosome membrane GO:0010008 9.56 TLR9 TLR4 TLR3 CFTR
3 cell surface GO:0009986 9.56 TLR4 TLR3 TLR2 MBL2 ELANE CLEC7A
4 extracellular space GO:0005615 9.4 TLR3 SFTPD PTX3 MBL2 IL5 IL4

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TLR9 TLR6 TLR4 TLR3 TLR2 IL5
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TLR9 TLR4 TLR3 TLR2 IL4 IL10
3 immune system process GO:0002376 10.2 TLR9 TLR6 TLR4 TLR3 TLR2 SFTPD
4 cytokine-mediated signaling pathway GO:0019221 10.11 IL5 IL4 IL10 CSF3 CSF1 CCL3
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.04 TLR9 TLR6 TLR4 TLR3 TLR2
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 TLR9 TLR6 TLR4 TLR3
7 response to lipopolysaccharide GO:0032496 10.03 TLR4 TLR2 IL10 ELANE
8 innate immune response GO:0045087 10.02 TLR9 TLR6 TLR4 TLR3 TLR2 SFTPD
9 positive regulation of inflammatory response GO:0050729 10 TLR9 TLR4 TLR3 TLR2 CCL3
10 cellular response to interferon-gamma GO:0071346 9.98 TLR4 TLR3 TLR2 CCL3
11 defense response to bacterium GO:0042742 9.97 TLR9 TLR6 TLR4 TLR3 SFTPD MBL2
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 TLR9 TLR4 TLR3 TLR2
13 positive regulation of interleukin-6 production GO:0032755 9.96 TLR9 TLR4 TLR3 TLR2
14 positive regulation of JNK cascade GO:0046330 9.93 TLR9 TLR4 TLR3
15 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TLR9 TLR4 TLR3
16 positive regulation of B cell proliferation GO:0030890 9.92 TLR9 TLR4 IL5 IL4
17 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.92 TLR9 TLR6 TLR4 TLR2
18 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR9 TLR4 TLR3 TLR2 CCL3
19 microglial cell activation GO:0001774 9.91 TLR6 TLR3 TLR2 IFNG
20 positive regulation of interleukin-8 production GO:0032757 9.9 TLR9 TLR4 TLR3 TLR2
21 positive regulation of interferon-beta production GO:0032728 9.89 TLR9 TLR4 TLR3 TLR2
22 positive regulation of phagocytosis GO:0050766 9.89 SFTPD PTX3 MBL2 IFNG CLEC7A
23 negative regulation of interleukin-6 production GO:0032715 9.88 TLR9 TLR4 IL10
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TLR4 TLR2 CCL3
25 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.87 TLR6 TLR4 TLR3
26 negative regulation of osteoclast differentiation GO:0045671 9.87 TLR4 TLR3 IL4 CCL3
27 positive regulation of chemokine production GO:0032722 9.86 TLR9 TLR4 TLR3 TLR2
28 positive regulation of interleukin-10 production GO:0032733 9.85 TLR9 TLR4 TLR2
29 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.85 TLR6 TLR4 CLEC7A
30 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.85 TLR4 IFNG CLEC7A
31 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TLR6 TLR4 PTX3 IFNG CLEC7A
32 positive regulation of gene expression GO:0010628 9.85 TLR9 TLR6 TLR4 TLR3 TLR2 IL4
33 positive regulation of macrophage activation GO:0043032 9.84 TLR6 TLR4 IL10
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.84 TLR9 TLR4 TLR2 IFNG
35 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.83 TLR9 TLR3 CLEC7A
36 regulation of cytokine secretion GO:0050707 9.83 TLR9 TLR6 TLR2
37 response to molecule of bacterial origin GO:0002237 9.82 TLR9 TLR2 IL10
38 cell activation GO:0001775 9.82 TLR6 TLR2 CCL3
39 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.81 TLR9 TLR4 ELANE CLEC7A
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.8 TLR9 TLR4 TLR3
41 positive regulation of interleukin-12 production GO:0032735 9.8 TLR9 TLR4 TLR3 TLR2 IFNG
42 I-kappaB phosphorylation GO:0007252 9.78 TLR9 TLR4 TLR3 TLR2
43 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.76 TLR6 TLR4
44 positive regulation of toll-like receptor signaling pathway GO:0034123 9.76 TLR9 TLR3 TLR2
45 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.75 TLR6 TLR4
46 positive regulation of chemokine biosynthetic process GO:0045080 9.75 TLR3 IFNG
47 cellular response to lipoteichoic acid GO:0071223 9.75 TLR4 TLR2
48 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
49 interleukin-1 beta secretion GO:0050702 9.75 TLR6 TLR4
50 negative regulation of interleukin-8 production GO:0032717 9.75 TLR9 IL10

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.43 TLR9 TLR6 TLR4 TLR3 TLR2 SFTPD
2 identical protein binding GO:0042802 10.01 TLR6 TLR4 TLR3 TLR2 SFTPD PTX3
3 carbohydrate binding GO:0030246 9.8 SFTPD MBL2 CLEC7A CLEC1A
4 signaling receptor activity GO:0038023 9.72 TLR6 TLR4 TLR3 TLR2 CCR6
5 amyloid-beta binding GO:0001540 9.7 TLR6 TLR4 TLR2
6 transmembrane signaling receptor activity GO:0004888 9.65 TLR9 TLR6 TLR4 TLR3 CLEC1A
7 lipopolysaccharide binding GO:0001530 9.61 TLR4 TLR2 SFTPD
8 growth factor activity GO:0008083 9.55 IL5 IL4 IL10 CSF3 CSF1
9 lipopeptide binding GO:0071723 9.51 TLR6 TLR2
10 lipopolysaccharide receptor activity GO:0001875 9.46 TLR4 TLR2
11 (1->3)-beta-D-glucan binding GO:0001872 9.37 PTX3 CLEC7A
12 cytokine activity GO:0005125 9.17 IL5 IL4 IL10 IFNG CSF3 CSF1
13 signaling pattern recognition receptor activity GO:0008329 9.13 TLR9 TLR2 CLEC7A

Sources for Aspergillosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....